Table 2 Definition of classification systems and distribution of the enrolled cases
From: The potential prognostic value of connexin 26 and 46 expression in neoadjuvant-treated breast cancer
| Classification system | Cases | Pathological response | ||||
|---|---|---|---|---|---|---|
| NSABP | pCR | 5 | No histological evidence of invasive tumour cells | |||
| pINV | 84 | Histological evidence of invasive disease of any extent | ||||
| Miller-Payne | G1 | 10 | Some alteration to individual malignant cells but no reduction in overall numbers as compared with the pre-treatment biopsy | |||
| G2 | 20 | A minor loss of invasive tumour cells but overall cellularity still high (<30%) | ||||
| G3 | 40 | A moderate reduction of in tumour cells up to an estimated 90% loss (30-90%) | ||||
| G4 | 14 | A marked disappearance of invasive tumour cells such that only small clusters of widely dispersed cells could be detected (>90%) | ||||
| G5 | 5 | No invasive tumours, i.e., only in situ disease or tumour stroma remained | ||||
| Sataloff | TA | 20 | Total or near total therapeutic effect | |||
| TB | 30 | Subjectively greater than 50 % therapeutic effect but less total and near total | ||||
| TC | 29 | Less than 50% therapeutic effect, but effect event | ||||
| TD | 10 | No therapeutic effect | ||||
| EWGBSP | TR1a | 4 | No residual tumour | |||
| TR1b | 1 | No residual invasive tumour but presence of residual in situ carcinoma | ||||
| TR2a | 14 | Minimal residual invasive tumour (<10%) | ||||
| TR2b | 31 | Therapeutic effect with residual invasive tumour (10-50%) | ||||
| TR2c | 29 | Therapeutic effect but >50% residual invasive tumour | ||||
| TR3 | 10 | No pathologic response | ||||
| CPS-EG | 0 | 0 | Point assignments | |||
| 1 | 2 | Clinical stage | Pathologic stage | Tumour marker | ||
| 2 | 19 | I; IIA = 0 | 0; I = 0 | ER negative =1 | G34 =1 | |
| 3 | 17 | IIB; IIIA = 1 | IIA/B; IIIA/B = 1 | |||
| 4 | 12 | IIIB; IIIC = 2 | IIIC = 2 | |||
| 5 | 5 | |||||
| 6 | 0 | |||||